Enhance your knowledge of CCA by listening to experts give their
perspectives on key topics in the educational videos below*
This online webinar took place on 26 February 2021 and was hosted by our esteemed faculty who critically discussed the complexity of diagnosing CCA and the clinical and genetic heterogeneity associated with the disease
Listen to Professor Eric Van Cutsem and Dr Angela Lamarca provide expert perspectives on key questions in precision medicine and molecular testing in advanced CCA
Company/Organisation | Relationship(s) |
---|---|
Personal financial interests: | |
Ability Pharmaceuticals SL, Aptitude Health, AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, Ellipses, Genzyme, Got It Consulting SL, Hirslanden/GITZ, Imedex, Incyte, Ipsen Bioscience, Inc, Janssen, Lilly, Marketing Farmacéutico & Investigación Clínica, S.L, MDS, Medscape, Novocure, Paraxel, PPD Development, Polaris, QED Therapeutics, Roche Farma, Sanofi-Aventis, Servier, Scilink Comunicación Científica SC, Surface Oncology, Swedish Orpahn Biovitrum AB, Zymeworks | Advisory role Speaker’s fee Direct research fund |
Institutional financial interests: | |
AbbVie Farmaceútica, Ability Pharmaceuticals, Agios Pharmaceuticals, Amc Medical Research, Amgen, Armo Biosciences, Aslan Pharmaceuticals, Astrazeneca, Basilea Pharmaceutica International, Bayer, Beigene, Biokeralty Research Institute, Biolinerx, Blueprint Medicines, Boston Biomedical, Bristol-Myers Squibb (BMS), Cantargia, Celgene, Eisai, Erytech Pharma, F. Hoffmann-la Roche, Fibrogen, Halozyme, Incyte, Ipsen Bioscience, Ipsen Pharma, Lilly, Loxo Oncology, Medimmune, Merck Sharp & Dohme, Nelum, Novartis, Novocure, Oncomed Pharmaceuticals, QED Therapeutics, VCN Biosciences, Zymeworks | Clinical trial support |
Company/Organisation | Relationship(s) |
---|---|
Bristol Myers Squibb, Bayer, Eisai, Gilead, Incyte, Intercept, Ipsen, MDS, Roche, Sanofi, Sigma-Tau | Consulting honoraria and advisory boards |
Company/Organisation | Relationship(s) |
---|---|
Albireo Pharma, AstraZeneca, Boston Scientific, EISAI, Ipsen, QED, Nutricia, Roche, Servier | Consulting honoraria |
AAA pharmaceuticals, AstraZeneca, EISAI, Incyte, Ipsen, QED, Merck, Pfizer, Servier | Speaker honoraria |
AAA pharmaceutical, Bayer, Delcath Systems, Ipsen, Mylan, Novartis, Pfizer, Sirtex Medical | Travel, education funding |
Company/Organisation | Relationship(s) |
---|---|
Incyte Biosciences International Sàrl | Former employee (01 May 2020 – 31 May 2022) |
Company/Organisation | Relationship(s) |
---|---|
Incyte | Consultant |
Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier | Research grants |
Array, Astellas, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi, Halozyme, GSK, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Pierre Fabre, Roche, Servier, Sirtex Medical, Taiho | Advisory boards |
Company/Organisation | Relationship(s) |
---|---|
Albireo Pharma, AstraZeneca, Boston Scientific, EISAI, Ipsen, QED, Nutricia, Roche, Servier | Consulting honoraria |
AAA pharmaceuticals, AstraZeneca, EISAI, Incyte, Ipsen, QED, Merck, Pfizer, Servier | Speaker honoraria |
AAA pharmaceutical, Bayer, Delcath Systems, Ipsen, Mylan, Novartis, Pfizer, Sirtex Medical | Travel, education funding |
You are now leaving Cholangiocarcinoma-eu.com. This link will take you to a site that is not owned or maintained by Incyte, and Incyte is not responsible for the information contained on third-party sites.
Please select from the following: